136 related articles for article (PubMed ID: 33067337)
1. Effects of Repeated
Yoshinaga K; Abe T; Okamoto S; Uchiyama Y; Manabe O; Ito YM; Tamura N; Ito N; Yoshioka N; Washino K; Shinohara N; Tamaki N; Shiga T
J Nucl Med; 2021 May; 62(5):685-694. PubMed ID: 33067337
[No Abstract] [Full Text] [Related]
2. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of (131)Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders.
Mulholland N; Chakravartty R; Devlin L; Kalogianni E; Corcoran B; Vivian G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):2002-12. PubMed ID: 26142730
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy of low activity meta-[131I]iodobenzylguanidine therapy in patients with disseminated neuroendocrine tumours depends on initial response.
Buscombe JR; Cwikla JB; Caplin ME; Hilson AJ
Nucl Med Commun; 2005 Nov; 26(11):969-76. PubMed ID: 16208174
[TBL] [Abstract][Full Text] [Related]
5. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET.
Menzel C; Graichen S; Berner U; Risse JH; Diehl M; Döbert N; Hamscho N; Grünwald F
Acta Med Austriaca; 2003; 30(2):37-40. PubMed ID: 12752086
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.
Binderup T; Knigge U; Loft A; Mortensen J; Pfeifer A; Federspiel B; Hansen CP; Højgaard L; Kjaer A
J Nucl Med; 2010 May; 51(5):704-12. PubMed ID: 20395333
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].
Mukherjee JJ; Kaltsas GA; Islam N; Plowman PN; Foley R; Hikmat J; Britton KE; Jenkins PJ; Chew SL; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2001 Jul; 55(1):47-60. PubMed ID: 11453952
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of using a standard activity of (131)I-MIBG therapy in patients with disseminated neuroendocrine tumours.
Navalkissoor S; Alhashimi DM; Quigley AM; Caplin ME; Buscombe JR
Eur J Nucl Med Mol Imaging; 2010 May; 37(5):904-12. PubMed ID: 20016892
[TBL] [Abstract][Full Text] [Related]
9. Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.
Castellani MR; Chiti A; Seregni E; Bombardieri E
Q J Nucl Med; 2000 Mar; 44(1):77-87. PubMed ID: 10932604
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with
Kane A; Thorpe MP; Morse MA; Howard BA; Oldan JD; Zhu J; Wong TZ; Petry NA; Reiman R; Borges-Neto S
J Nucl Med; 2018 Nov; 59(11):1708-1713. PubMed ID: 29777005
[TBL] [Abstract][Full Text] [Related]
12. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and Dosimetry of
Pandit-Taskar N; Zanzonico P; Staton KD; Carrasquillo JA; Reidy-Lagunes D; Lyashchenko S; Burnazi E; Zhang H; Lewis JS; Blasberg R; Larson SM; Weber WA; Modak S
J Nucl Med; 2018 Jan; 59(1):147-153. PubMed ID: 28705916
[No Abstract] [Full Text] [Related]
14. Long-term outcome and toxicity after dose-intensified treatment with 131I-MIBG for advanced metastatic carcinoid tumors.
Ezziddin S; Sabet A; Logvinski T; Alkawaldeh K; Yong-Hing CJ; Ahmadzadehfar H; Grünwald F; Biersack HJ
J Nucl Med; 2013 Dec; 54(12):2032-8. PubMed ID: 24101685
[TBL] [Abstract][Full Text] [Related]
15. 131I-MIBG Therapy in a Metastatic Small Bowel Neuroendocrine Tumor Patient Undergoing Hemodialysis.
Rahimi B; Makis W; Riauka TA; McEwan AJ; Morrish D
Clin Nucl Med; 2017 May; 42(5):350-353. PubMed ID: 28240668
[TBL] [Abstract][Full Text] [Related]
16. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
17. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
[TBL] [Abstract][Full Text] [Related]
18. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
19. Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging.
Zhang-Yin J; Dirand AS; Sasanelli M; Corrégé G; Peudon A; Kiffel T; Nataf V; Clerc J; Montravers F; Talbot JN
J Nucl Med; 2017 Aug; 58(8):1230-1235. PubMed ID: 28209907
[No Abstract] [Full Text] [Related]
20. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans.
Monsieurs M; Brans B; Bacher K; Dierckx R; Thierens H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1581-7. PubMed ID: 12458391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
